Landscape Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Landscape Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-6,375	Closed	-$298K	–	667
2017 Q3	$298K	Sell	6,375 -12,209	-66%	-$491K	0.03%	399
2017 Q2	$669K	Hold	18,584	–	–	0.08%	175
2017 Q1	$572K	Buy	+18,584	New	+$579K	0.06%	270
2016 Q3	–	Sell	-53,415	Closed	-$1.18M	–	480
2016 Q2	$1.18M	Sell	53,415 -31,843	-37%	-$833K	0.16%	160
2016 Q1	$2.5M	Buy	85,258 +46,415	+119%	+$1.29M	0.3%	86
2015 Q4	$1.28M	Buy	38,843 +5,443	+16%	+$177K	0.16%	154
2015 Q3	$1.21M	Buy	33,400 +1,400	+4%	+$60.1K	0.16%	113
2015 Q2	$1.44M	Buy	32,000 +22,046	+221%	+$858K	0.24%	90
2015 Q1	$305K	Buy	+9,954	New	+$387K	0.08%	347

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Landscape Capital Management's ENTA Position: Q4 2017 in Review

Landscape Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2017, closing a stake of 6,375 shares — an estimated $298K sold.

Landscape Capital Management first reported a position in ENTA in Q1 2015 and held it in 9 quarters. The position peaked at $2.5M in Q1 2016. 148 funds tracked by Wall St. Rank hold ENTA as of Q4 2017.

Landscape Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Landscape Capital Management sold 6,375 Enanta Pharmaceuticals shares in Q4 2017, an estimated $298K.
Landscape Capital Management first reported a position in Enanta Pharmaceuticals in Q1 2015 and held it in 9 quarters.
Landscape Capital Management's Enanta Pharmaceuticals position peaked at $2.5M in Q1 2016.
148 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2017.

Based on Landscape Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.